Sumitomo Mitsui Trust Group
PRME icon

Sumitomo Mitsui Trust Group’s Prime Medicine PRME Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2M Sell
2,940,793
-304,713
-9% -$1.16M 0.01% 669
2025
Q4 		$11.3M Sell
3,245,506
-384,418
-11% -$1.71M 0.01% 672
2025
Q3 		$20.1M Buy
3,629,924
+2,035,406
+128% +$8.27M 0.01% 643
2025
Q2 		$3.94M Sell
1,594,518
-1,331,505
-46% -$2.05M ﹤0.01% 736
2025
Q1 		$5.82M Sell
2,926,023
-164,157
-5% -$419K ﹤0.01% 723
2024
Q4 		$9.02M Sell
3,090,180
-100,275
-3% -$352K 0.01% 713
2024
Q3 		$12.3M Sell
3,190,455
-47,930
-1% -$222K 0.01% 693
2024
Q2 		$16.6M Sell
3,238,385
-126,278
-4% -$766K 0.01% 663
2024
Q1 		$23.6M Sell
3,364,663
-154,366
-4% -$1.17M 0.02% 682
2023
Q4 		$31.2M Sell
3,519,029
-115,819
-3% -$892K 0.02% 611
2023
Q3 		$34.7M Buy
3,634,848
+571,097
+19% +$7.42M 0.03% 564
2023
Q2 		$44.9M Buy
3,063,751
+2,066,179
+207% +$28.8M 0.04% 503
2023
Q1 		$12.3M Buy
997,572
+509,346
+104% +$8.3M 0.01% 773
2022
Q4 		$9.07M Buy
+488,226
New +$8.82M 0.01% 793

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group's PRME Position: Q1 2026 in Review

Sumitomo Mitsui Trust Group reduced its Prime Medicine (PRME) stake by 9.4% in Q1 2026, selling an estimated $1.16M and leaving 2,940,793 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #669.

Sumitomo Mitsui Trust Group first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $44.9M in Q2 2023. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Sumitomo Mitsui Trust Group held 2,940,793 shares of Prime Medicine worth $10.2M as of Q1 2026.
  • Sumitomo Mitsui Trust Group sold 304,713 Prime Medicine shares in Q1 2026, an estimated $1.16M.
  • Prime Medicine made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q1 2026, its #669 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Sumitomo Mitsui Trust Group's Prime Medicine position peaked at $44.9M in Q2 2023.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2026, filed 30 Apr 2026.